Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients with Cancer
Protocol ID
AMXT1501-102
Disease (Sub Disease)
All Cancer Types
Diagnosis Stage
"New diagnosis
Relapse/refractory"
Relapse/refractory"
Location
NSW
Sponsor
Aminex Therapeutics, Inc.
Links
Trial Status
Open
Sites
Sydney Children's Hospital
Study Type
Interventional
Phase
Phase 1/2
Age Eligibility
12 years and older (12year - 17 years separate eligibility)
International registry ID's
NCT05500508
| Study Title | A Phase 1B/2A Study of the Safety Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients with Cancer |
|---|---|
| Protocol ID | AMXT1501-102 |
| Disease (Sub Disease) | All Cancer Types |
| Diagnosis Stage | "New diagnosis Relapse/refractory" |
| Location | NSW |
| Sponsor | Aminex Therapeutics, Inc. / |
| Links | https://clinicaltrials.gov/study/NCT05500508 |
| Trial Status | Open |
| Trial Open Date | 29/11/2022 |
| Sites | Sydney Children's Hospital |
| Study Type | Interventional |
| Phase | Phase 1/2 |
| Age Eligibility | 12 years and older (12year - 17 years separate eligibility) |
| International registry ID's | NCT05500508 |